Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Extension of the Launay Quantum Reactive Scattering Code and Direct Computation of Time Delays.

Privat E, Guillon G, Honvault P.

J Chem Theory Comput. 2019 Oct 8;15(10):5194-5198. doi: 10.1021/acs.jctc.9b00635. Epub 2019 Sep 13.

PMID:
31469567
2.

Quantum mechanical study of the 16O + 18O18O → 16O18O + 18O exchange reaction: Integral cross sections and rate constants.

Honvault P, Guillon G, Kochanov R, Tyuterev V.

J Chem Phys. 2018 Dec 7;149(21):214304. doi: 10.1063/1.5053469.

PMID:
30525723
3.

Correction: Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test.

Guillon G, Yearwood G, Snipes C, Boschi D, Reed MR.

PeerJ. 2018 Jun 22;6. pii: e4430/correction-1. doi: 10.7717/peerj.4430/correction-1. eCollection 2018.

4.

First-Principles Computed Rate Constant for the O + O2 Isotopic Exchange Reaction Now Matches Experiment.

Guillon G, Honvault P, Kochanov R, Tyuterev V.

J Phys Chem Lett. 2018 Apr 19;9(8):1931-1936. doi: 10.1021/acs.jpclett.8b00661. Epub 2018 Apr 3.

PMID:
29595990
5.

Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test.

Guillon G, Yearwood G, Snipes C, Boschi D, Reed MR.

PeerJ. 2018 Feb 28;6:e4430. doi: 10.7717/peerj.4430. eCollection 2018. Erratum in: PeerJ. 2018 Jun 22;6:.

6.

Neuroanatomical distribution and function of the vasopressin V1B receptor in the rat brain deciphered using specific fluorescent ligands.

Corbani M, Marir R, Trueba M, Chafai M, Vincent A, Borie AM, Desarménien MG, Ueta Y, Tomboly C, Olma A, Manning M, Guillon G.

Gen Comp Endocrinol. 2018 Mar 1;258:15-32. doi: 10.1016/j.ygcen.2017.10.011. Epub 2017 Nov 17.

PMID:
29155265
7.

Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1A receptors.

Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N.

Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E127-E135. doi: 10.1152/ajpendo.00269.2016. Epub 2016 Dec 20.

8.

Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile.

Colson PH, Virsolvy A, Gaudard P, Charrabi A, Corbani M, Manière MJ, Richard S, Guillon G.

Pharmacol Res. 2016 Nov;113(Pt A):257-264. doi: 10.1016/j.phrs.2016.08.027. Epub 2016 Aug 29.

PMID:
27586252
9.

Quantum Dynamics of the 17O + 32O2 Collision Process.

Guillon G, Honvault P.

J Phys Chem A. 2016 Oct 27;120(42):8254-8258. doi: 10.1021/acs.jpca.6b07547. Epub 2016 Oct 13.

PMID:
27712065
10.

A GIPC1-Palmitate Switch Modulates Dopamine Drd3 Receptor Trafficking and Signaling.

Arango-Lievano M, Sensoy O, Borie A, Corbani M, Guillon G, Sokoloff P, Weinstein H, Jeanneteau F.

Mol Cell Biol. 2016 Jan 19;36(6):1019-31. doi: 10.1128/MCB.00916-15.

11.

Differential Cross Sections and Product Rovibrational Distributions for (16)O + (32)O2 and (18)O + (36)O2 Collisions.

Rao TR, Guillon G, Mahapatra S, Pascal Honvault.

J Phys Chem A. 2015 Nov 19;119(46):11432-9. doi: 10.1021/acs.jpca.5b08638. Epub 2015 Nov 10.

PMID:
26524085
12.

Quantum Dynamics of the (18)O + (36)O2 Collision Process.

Guillon G, Rao TR, Mahapatra S, Honvault P.

J Phys Chem A. 2015 Dec 17;119(50):12512-6. doi: 10.1021/acs.jpca.5b08163. Epub 2015 Oct 20.

PMID:
26437007
13.

Huge Quantum Symmetry Effect in the O + O2 Exchange Reaction.

Rao TR, Guillon G, Mahapatra S, Honvault P.

J Phys Chem Lett. 2015 Feb 19;6(4):633-6. doi: 10.1021/jz5026257. Epub 2015 Feb 2.

PMID:
26262478
14.

Quantum dynamics of (16)O + (36)O2 and (18)O + (32)O2 exchange reactions.

Rajagopala Rao T, Guillon G, Mahapatra S, Honvault P.

J Chem Phys. 2015 May 7;142(17):174311. doi: 10.1063/1.4919860.

PMID:
25956104
15.

An Early Postnatal Oxytocin Treatment Prevents Social and Learning Deficits in Adult Mice Deficient for Magel2, a Gene Involved in Prader-Willi Syndrome and Autism.

Meziane H, Schaller F, Bauer S, Villard C, Matarazzo V, Riet F, Guillon G, Lafitte D, Desarmenien MG, Tauber M, Muscatelli F.

Biol Psychiatry. 2015 Jul 15;78(2):85-94. doi: 10.1016/j.biopsych.2014.11.010. Epub 2014 Nov 20.

PMID:
25599930
16.

A new post-quantization constrained propagator for rigid tops for use in path integral quantum simulations.

Guillon G, Zeng T, Roy PN.

J Chem Phys. 2013 Nov 14;139(18):184115. doi: 10.1063/1.4829506.

PMID:
24320262
17.

Acaricide activity of different extracts from Piper tuberculatum fruits against Rhipicephalus microplus.

Lima Ada S, Sousa Filho JG, Pereira SG, Guillon GM, Santos Lda S, Costa Júnior LM.

Parasitol Res. 2014 Jan;113(1):107-12. doi: 10.1007/s00436-013-3632-8. Epub 2013 Nov 13.

PMID:
24221883
18.

Probing the Superfluid Response of para-Hydrogen with a Sulfur Dioxide Dopant.

Zeng T, Guillon G, Cantin JT, Roy PN.

J Phys Chem Lett. 2013 Jul 18;4(14):2391-6. doi: 10.1021/jz401188j. Epub 2013 Jul 9.

PMID:
26704292
19.

Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Marir R, Virsolvy A, Wisniewski K, Mion J, Haddou D, Galibert E, Meraihi Z, Desarménien MG, Guillon G.

Br J Pharmacol. 2013 Sep;170(2):278-92. doi: 10.1111/bph.12249.

20.

On the origin and convergence of a Post-Quantization Constrained propagator for path integral simulations of rigid bodies.

Guillon G, Zeng T, Roy PN.

J Chem Phys. 2013 May 14;138(18):184101. doi: 10.1063/1.4803118.

PMID:
23676023
21.

Vasopressin inhibits LTP in the CA2 mouse hippocampal area.

Chafai M, Corbani M, Guillon G, Desarménien MG.

PLoS One. 2012;7(12):e49708. doi: 10.1371/journal.pone.0049708. Epub 2012 Dec 7.

22.

Full dimension Rb2He ground triplet potential energy surface and quantum scattering calculations.

Guillon G, Viel A, Launay JM.

J Chem Phys. 2012 May 7;136(17):174307. doi: 10.1063/1.4709433.

PMID:
22583230
23.

Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Oligny-Longpré G, Corbani M, Zhou J, Hogue M, Guillon G, Bouvier M.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):E1028-37. doi: 10.1073/pnas.1112422109. Epub 2012 Apr 9.

24.

Excited Li and Na in He(n): influence of the dimer potential energy curves.

Dell'Angelo D, Guillon G, Viel A.

J Chem Phys. 2012 Mar 21;136(11):114308. doi: 10.1063/1.3693766.

PMID:
22443765
25.

Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G.

J Neuroendocrinol. 2012 Apr;24(4):609-28. doi: 10.1111/j.1365-2826.2012.02303.x. Review.

26.

V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Murat B, Devost D, Andrés M, Mion J, Boulay V, Corbani M, Zingg HH, Guillon G.

Mol Endocrinol. 2012 Mar;26(3):502-20. doi: 10.1210/me.2011-1202. Epub 2012 Feb 2.

27.

Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration.

Colson PH, Bernard C, Struck J, Morgenthaler NG, Albat B, Guillon G.

Crit Care. 2011;15(5):R255. doi: 10.1186/cc10516. Epub 2011 Oct 25.

28.

Theoretical study of Rb2 in He(N): potential energy surface and Monte Carlo simulations.

Guillon G, Zanchet A, Leino M, Viel A, Zillich RE.

J Phys Chem A. 2011 Jun 30;115(25):6918-26. doi: 10.1021/jp112053b. Epub 2011 Mar 24.

PMID:
21434656
29.

Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

Corbani M, Trueba M, Stoev S, Murat B, Mion J, Boulay V, Guillon G, Manning M.

J Med Chem. 2011 Apr 28;54(8):2864-77. doi: 10.1021/jm1016208. Epub 2011 Mar 23.

30.

Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid.

Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M.

J Virol Methods. 2011 Mar;172(1-2):27-31. doi: 10.1016/j.jviromet.2010.12.009. Epub 2010 Dec 21.

PMID:
21182871
31.

Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection.

Lee SR, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Friel T, Berne CA, Kardos KW.

J Clin Virol. 2010 May;48(1):15-7. doi: 10.1016/j.jcv.2010.02.018. Epub 2010 Apr 1.

PMID:
20362493
32.

VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist.

Rihakova L, Quiniou C, Hamdan FF, Kaul R, Brault S, Hou X, Lahaie I, Sapieha P, Hamel D, Shao Z, Gobeil F Jr, Hardy P, Joyal JS, Nedev H, Duhamel F, Beauregard K, Heveker N, Saragovi HU, Guillon G, Bouvier M, Lubell WD, Chemtob S.

Am J Physiol Regul Integr Comp Physiol. 2009 Oct;297(4):R1009-18. doi: 10.1152/ajpregu.90766.2008. Epub 2009 Jul 29.

34.

Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance.

Ryckwaert F, Virsolvy A, Fort A, Murat B, Richard S, Guillon G, Colson PH.

Crit Care Med. 2009 Mar;37(3):876-81. doi: 10.1097/CCM.0b013e31819b8199.

PMID:
19237891
35.

Rotational relaxation of HF by collision with ortho- and para-H2 molecules.

Guillon G, Stoecklin T, Voronin A, Halvick P.

J Chem Phys. 2008 Sep 14;129(10):104308. doi: 10.1063/1.2975194.

PMID:
19044914
36.

Sustained elevated levels of circulating vasopressin selectively stimulate the proliferation of kidney tubular cells via the activation of V2 receptors.

Alonso G, Galibert E, Boulay V, Guillou A, Jean A, Compan V, Guillon G.

Endocrinology. 2009 Jan;150(1):239-50. doi: 10.1210/en.2008-0068. Epub 2008 Sep 11.

PMID:
18787031
37.

Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.

Chini B, Manning M, Guillon G.

Prog Brain Res. 2008;170:513-7. doi: 10.1016/S0079-6123(08)00438-X.

PMID:
18655904
38.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.

Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Review.

PMID:
18655903
39.

Intrahypothalamic angiogenesis induced by osmotic stimuli correlates with local hypoxia: a potential role of confined vasoconstriction induced by dendritic secretion of vasopressin.

Alonso G, Gallibert E, Lafont C, Guillon G.

Endocrinology. 2008 Sep;149(9):4279-88. doi: 10.1210/en.2008-0387. Epub 2008 May 15.

PMID:
18483147
40.

The multifunctional protein GC1q-R interacts specifically with the i3 loop arginine cluster of the vasopressin V2 receptor.

Granier S, Jean-Alphonse F, Bacqueville D, Monteil A, Pascal R, Poncet J, Guillon G, Boudier L, Arcemisbéhère L, Mouillac B, Bellot G, Déméné H, Mendre C.

Regul Pept. 2008 Jun 5;148(1-3):76-87. doi: 10.1016/j.regpep.2008.01.007. Epub 2008 Feb 2.

PMID:
18358546
41.

Conopressin-T from Conus tulipa reveals an antagonist switch in vasopressin-like peptides.

Dutertre S, Croker D, Daly NL, Andersson A, Muttenthaler M, Lumsden NG, Craik DJ, Alewood PF, Guillon G, Lewis RJ.

J Biol Chem. 2008 Mar 14;283(11):7100-8. doi: 10.1074/jbc.M706477200. Epub 2008 Jan 2.

42.

Vasopressin-induced morphological changes in polarized rat hepatocyte multiplets: dual calcium-dependent effects.

Serrière V, Tran D, Stelly N, Claret M, Alonso G, Tordjmann T, Guillon G.

Cell Calcium. 2008 Jan;43(1):95-104. Epub 2007 Jun 6.

PMID:
17555812
43.

Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.

Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL, Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C, Manning M, Guillon G.

Endocrinology. 2007 Sep;148(9):4136-46. Epub 2007 May 10.

PMID:
17495006
44.

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.

J Med Chem. 2007 Feb 22;50(4):835-47.

PMID:
17300166
45.

Remodelling of calcium signalling during liver regeneration in the rat.

Nicou A, Serrière V, Hilly M, Prigent S, Combettes L, Guillon G, Tordjmann T.

J Hepatol. 2007 Feb;46(2):247-56. Epub 2006 Oct 9.

PMID:
17125880
46.

Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors.

Rodrigo J, Pena A, Murat B, Trueba M, Durroux T, Guillon G, Rognan D.

Mol Endocrinol. 2007 Feb;21(2):512-23. Epub 2006 Nov 2.

PMID:
17082326
47.

Design and synthesis of cyclic and linear peptide-agarose tools for baiting interacting protein partners of GPCRs.

Granier S, Jean-Alphonse F, Déméné H, Guillon G, Pascal R, Mendre C.

Bioorg Med Chem Lett. 2006 Feb;16(3):521-4. Epub 2005 Nov 11.

PMID:
16289816
48.

Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.

Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.

J Pept Sci. 2006 Mar;12(3):190-8.

PMID:
16130178
49.

Cumulative effects of AT1 and AT2 receptor blockade on ischaemia-reperfusion recovery in rat hearts.

Ryckwaert F, Colson P, Guillon G, Foëx P.

Pharmacol Res. 2005 Jun;51(6):497-502.

PMID:
15829428
50.

Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.

Andrés M, Peña A, Derick S, Raufaste D, Trojnar J, Wisniewski K, Trueba M, Serradeil-Le Gal C, Guillon G.

Eur J Pharmacol. 2004 Oct 6;501(1-3):59-69.

PMID:
15464063

Supplemental Content

Loading ...
Support Center